Delving into the Latest Updates on M101 with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

m101

Target

TIM3

Action

inhibitors

Mechanism

TIM3 inhibitors(Hepatitis A virus cellular receptor 2 inhibitors)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Fudan University

Active Organization

Fudan University

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Postmastectomy skin-flap necrosis after nipple-sparing mastectomy (NSM) is common and exceeds rates after skin-sparing mastectomy (SSM) (0-19.5 %), influenced by patient factors and modifiable intraoperative variables. Presentations range from superficial necrosis to full-thickness necrosis requiring surgical debridement. These events drive reoperation or implant loss, may delay adjuvant therapy, and burden patients psychologically. Clinical examination and ancillary tests poorly discriminate depth; thus, management usually entails close observation until demarcation, followed by targeted intervention. M101, a hemoglobin-based oxygen carrier, demonstrates anti-ischemia-reperfusion effects and promise in advanced wounds. We report two NSM cases with partial skin-flap and nipple-areola complex necrosis managed with an M101-based oxygenating dressing (HemHealing®; Hemarina SA, Morlaix, France), with ultimately no surgical debridement required.

01 Nov 2025·CLINICAL ORAL IMPLANTS RESEARCH

Evaluation of a Gel Loaded With M101 on Bone and Peri‐Implantitis Healing: An Experimental In Vivo Study

Article

Author: Renaudineau, Yves ; Gegout, Pierre‐Yves ; Petit, Catherine ; Muñoz, Fernando ; González, Mario García ; Puissant, Bénédicte ; López‐Peña, Mónica ; Le Gall, Camille ; Leize‐Zal, Elisabeth ; Permuy, Maria ; Stutz, Céline ; Zal, Franck ; Huck, Olivier

ABSTRACT:

Objectives:

The aim of this study was to evaluate the effect of M101 gel in bone and peri‐implantitis healing and its safety of use.

Materials and Methods:

M101 gel and solution (1 g/L) were evaluated in four different models: (i) human osteoblast culture; (ii) mouse calvarial defect; (iii) extraction model in dogs; (iv) peri‐implantitis model in dogs. M101 cytocompatibility was evaluated in osteoblasts, and expression of ALP, Runx2, and BMP‐2 was determined. Calvarial defect was induced in mice by bone drilling, and healing was evaluated after 5 weeks. In dogs, peri‐implantitis was treated by non‐surgical and surgical approaches with or without M101 gel application. Analyses were performed after 2 months. Socket healing was evaluated by micro‐CT after tooth extraction. Local and systemic responses were evaluated after gel administration and intravenous injection.

Results:

The cytocompatibility of M101 was confirmed in osteoblasts, and ALP, Runx2, and BMP‐2 gene expression was increased after exposure ( p < 0.05). In mice, calvarial bone defect healing was 1.6 folds more in the M101 gel treated group than in the untreated group ( p < 0.001). In the extraction model, the local M101 gel application and systemic M101 administration did not induce an immunological response. In the peri‐implantitis dog model, M101 gel as an adjuvant to non‐surgical treatment led to improved PiPD reduction ( p < 0.05) when compared to non‐surgical treatment without M101 gel. No difference was observed when used as an adjunct to surgical treatment.

Conclusion:

M101 may be a safe and interesting candidate as an adjuvant to improve bone healing and non‐surgical treatment in peri‐implantitis.

01 Sep 2025·ARTIFICIAL ORGANS

Investigating M101 's Effect in Improving Cardiac and Diaphragmatic Mechanical and Functional Properties on Wistar Rat

Article

Author: Quéméneur, Jean‐Baptiste ; Grimault, Ollivier ; Pichavant‐Rafini, Karine ; Maalouf, Mathieu ; Zal, Franck ; Léon, Karelle ; Boete, Quentin ; Theron, Michael

ABSTRACT:

Background:

The critical importance of effective oxygen delivery during organ preservation to prevent ischemia–reperfusion injury has been reported in the literature. Moreover, traditional preservation methods often fail to meet oxygenation needs, prompting research into alternatives like hemoglobin‐based oxygen carriers (HBOCs) such as M101 provided by HEMARINA. This extracellular hemoglobin, derived from Arenicola marina , shows a high affinity for oxygen and delivers it through a physiological gradient under hypoxic conditions.

Methods:

In this context, the mechanical and functional properties of the heart and diaphragm muscles from Wistar rats were evaluated in the presence of M101.

Results:

The experiments showed that M101‐treated hearts maintained higher contraction amplitudes, heart rates, and coronary flow over time compared to controls, indicating improved functional stability. Furthermore, the M101‐treated diaphragm exhibited prolonged contraction and relaxation times, with significant improvements in contraction amplitude at higher stimulation frequencies. Finally, the Burke index revealed reduced fatigue in the M101‐treated group compared to the controls.

Conclusions:

These findings suggest that M101 significantly enhances the mechanical and functional properties of both tested muscles under experimental conditions. Further research is warranted to unravel these findings and explore clinical applications.

100 Deals associated with M101

Login to view more data

R&D Status

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data